Superworth

Petmed Express price to free cash flow PETS

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
58.5×
Oct 2025
10-year median
18.2×
10-year range
5.1× to 107×
Peer median
11.8×

Petmed Express' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Oct 2025, at 58.5×.

On the days it had one over the last ten years, its median was 18.2×, from 5.1× in Apr 2024 to 107× in Feb 2025.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202558.5×58.5×107×
202453.2×5.1×56.2×
20239.2×8.7×24.0×
202219.2×15.9×27.5×
202122.3×11.2×27.0×
202019.3×11.4×27.7×
201911.3×6.9×23.0×
201812.7×12.0×33.6×
201728.7×17.1×52.4×
201652.7×13.4×459×
201516.0×10.6×26.3×
201423.5×12.2×37.4×
201315.3×9.2×26.6×
201211.3×7.9×12.9×

Against its peers

Companies in Healthcare nearest Petmed Express' size, closest first, today.

CompanyPrice to free cash flow
PETSPetmed Expressn/m
NEPHNephrosn/m
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech9.7×
SPROSpero Therapeuticsn/m
LFVNLifevantage11.0×
ICCCImmucell22.1×
KEQUKewaunee Scientific8.7×
PDEXPro DEX29.5×
PLXProtalix BioTherapeutics26.8×
NATRNatures Sunshine Products11.8×
Peer median11.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Petmed Express

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.